Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP7 | P55210 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011377 | 0.86 | MEN1 (0.43) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL3001985 | 0.84 | CSNK2A2 (0.43) | NPC1ATML3MBTL1MEN1KMT2A | |
| SCHEMBL4002259 | 0.84 | MEN1 (0.43) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL3000830 | 0.82 | GAA (0.44) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL3007525 | 0.81 | CSNK2A2 (0.40) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL3011737 | 0.81 | CSNK2A2 (0.41) | NPC1ATML3MBTL1MEN1KMT2A | |
| SCHEMBL3001182 | 0.79 | MTNR1A (0.44) | NPC1ATML3MBTL1CSNK2A2CSNK2B | |
| SCHEMBL4001839 | 0.79 | CSNK2A2 (0.41) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL2997489 | 0.79 | ALDH1A1 (0.45) | NPC1MEN1KMT2AKDM4ECYP3A4 | |
| SCHEMBL4008506 | 0.78 | CSNK2A2 (0.48) | MEN1KMT2AKDM4ECYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069321-B1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | MEDIFRON DBT CO LTD (KR) | 2016-04-13 | — | — | EP | claimed |
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2010-08-05 | — | — | US | claimed |
| EP-2069321-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | Digital Biotech Co., Ltd. (KR) | 2009-06-17 | — | — | EP | claimed |
| WO-2008041826-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2008-04-10 | — | — | WO | claimed |
| EP-2069321-B1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | MEDIFRON DBT CO LTD (KR) | 2016-04-13 | — | — | EP | disclosed |
| US-8580848-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-11-12 | — | — | US | disclosed |
| US-8507553-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-13 | — | — | US | disclosed |
| US-8455542-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-06-04 | — | — | US | disclosed |
| US-20120259006-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-10-11 | — | — | US | disclosed |
| US-20120245165-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245225-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-09-27 | — | — | US | disclosed |
| US-8263649-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | MEDIFRON DBT CO., LTD. (KR) | 2012-09-11 | — | — | US | disclosed |
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2010-08-05 | — | — | US | disclosed |
| EP-2069321-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | Digital Biotech Co., Ltd. (KR) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008041826-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | NPC1 1675/4885ATM 2297/4885L3MBTL1 1175/4885 |
| US-20120259006-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | NPC1 1675/4885ATM 2297/4885L3MBTL1 1175/4885 |
| US-20120245165-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | NPC1 1675/4885ATM 2297/4885L3MBTL1 1175/4885 |
| US-20120245225-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | NPC1 1675/4885ATM 2297/4885L3MBTL1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.